BK

Brijendra Kumar

Active Director Director DIN 07965156
DIN 07965156 First appointment Oct 2017 Primary industry E-Commerce
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2017
Shareholding value •••• Premium profile

About Brijendra Kumar

Data last updated:

Brijendra Kumar is a Director at Buy Drug Private Limited (since 2017). The company operates in E-Commerce. Buy Drug Private Limited reported revenue of ₹22.7 Lakh (FY 2017).

DIN 07965156
Primary Designation Director
Industry E-Commerce
First Appointment 16 Oct 2017
Oldest Company Age 13 yrs
Largest company Buy Drug Private Limited · ₹22.7 Lakh (FY 2017)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Buy Drug Private Limited U74999DL2013PTC259076
Director16 Oct 20172013₹22.7 Lakh (FY 2017)Active

Board colleagues of Brijendra Kumar

NameDINCompanyDesignation
Sudha Dwivedi07512418Buy Drug Private LimitedDirector

Directorship timeline

Open interactive timeline →
Buy Drug Private Limited
Premium access

Shareholding and investment profile for Brijendra Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Brijendra Kumar

Brijendra Kumar currently holds 1 directorship: Buy Drug Private Limited (Director, since 16 Oct 2017, revenue ₹22.7 Lakh (FY 2017)).

Brijendra Kumar was first appointed on 16 Oct 2017 as Director at Buy Drug Private Limited.

The current boards of Brijendra Kumar's companies include Sudha Dwivedi (Buy Drug Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available